Dynamk Capital Announces First Closing and Launch of Life Sciences Venture Fund
ENGLEWOOD CLIFFS, N.J., Sept. 26, 2017 /PRNewswire/ -- Dynamk Capital has announced a first close for its venture fund providing early stage capital to innovative companies providing tools, technologies and services within the Life Sciences sector. The fund is on track for a final close in 2018 and expects to invest in 8-10 companies over the next several years. Since founding in 2016, Dynamk has been actively cultivating deal flow as well as relationships with limited partners and strategic investors.
"We are excited about the strong support of the fund at this early stage, especially among leaders in the sector," said Daniella Kranjac, Managing Partner of Dynamk Capital. "Investors in our fund will be provided with the opportunity to engage in the discovery and production of life-saving therapies, and ultimately making these medicines more accessible. They also appreciate our model of leveraging growth in biopharmaceutical sector, and mitigating risk by focusing our investments on the tools critical to the industry."
Dynamk's portfolio companies will provide technologies and services that enable biopharmaceutical companies around the world to develop therapeutics faster and produce them more economically. By focusing on enabling tools utilized across the industry, Dynamk's model leverages the growth of the several hundred billion-dollar biopharmaceutical industry, while mitigating risks inherent to therapeutics.
Kranjac commented, "With investment commitments now confirmed, we can advance and invest in opportunities already on our deal radar. The entrepreneurs in this sector appreciate that we have the experience of successfully developing, launching and driving adoption for disruptive technologies across life sciences. They view us as a differentiated investor with sector-specific expertise, and we look forward to helping them accelerate their growth and achieve success."
About Dynamk Capital
Dynamk Capital LLC is a venture capital firm investing in early stage life sciences companies. Dynamk's investment strategy is centered on identifying companies developing disruptive technologies, tools and services that enable the full biopharma continuum across discovery, development and manufacturing of therapeutics. The Dynamk team includes experienced life science entrepreneurs, investors, advisors and subject matter experts. Please visit www.dynamk.vc for more information.
Contacts
Media and Investors:
Dynamk Capital LLC
[email protected]
SOURCE Dynamk Capital
Share this article